Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study

G. Folprecht, Thierry André, Elena Élez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Ariel Mendez, M. Schenker, Christelle de la Fouchardière, María Luisa Limón, Takashi Yoshino, J. Li, Heinz-Josef Lenz, J. Manzano Mozo, Giampaolo Tortora, R. Garcia-Carbonero, Elena Cela, Yiqun Yang, Ming Lei, L. Jin, Sara Lonardi